

Jan Volavka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4396532/publications.pdf>

Version: 2024-02-01

189
papers

11,017
citations

30070

54
h-index

32842

100
g-index

196
all docs

196
docs citations

196
times ranked

7485
citing authors

#	ARTICLE	IF	CITATIONS
1	The Catechol-O-Methyltransferase Polymorphism: Relations to the Tonicâ€“Phasic Dopamine Hypothesis and Neuropsychiatric Phenotypes. <i>Neuropsychopharmacology</i> , 2004, 29, 1943-1961.	5.4	704
2	Neurocognitive Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol in Patients With Chronic Schizophrenia or Schizoaffective Disorder. <i>American Journal of Psychiatry</i> , 2002, 159, 1018-1028.	7.2	493
3	Changes in Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical Antipsychotics. <i>American Journal of Psychiatry</i> , 2003, 160, 290-296.	7.2	450
4	Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder. <i>American Journal of Psychiatry</i> , 2002, 159, 255-262.	7.2	377
5	Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. <i>BMJ: British Medical Journal</i> , 2006, 333, 224.	2.3	317
6	Neurocognitive correlates of the COMT Val158Met polymorphism in chronic schizophrenia. <i>Biological Psychiatry</i> , 2002, 52, 701-707.	1.3	304
7	Mental disorder and violence: is there a relationship beyond substance use?. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2012, 47, 487-503.	3.1	265
8	Association between low activity serotonin transporter promoter genotype and early onset alcoholism with habitual impulsive violent behavior. <i>Molecular Psychiatry</i> , 1999, 4, 385-388.	7.9	222
9	CatecholO-Methyltransferase Val158Met Polymorphism in Schizophrenia: Differential Effects of Val and Met Alleles on Cognitive Stability and Flexibility. <i>American Journal of Psychiatry</i> , 2004, 161, 359-361.	7.2	213
10	Frontal white matter microstructure, aggression, and impulsivity in men with schizophrenia: a preliminary study. <i>Biological Psychiatry</i> , 2002, 52, 9-14.	1.3	204
11	Analysis of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association with aggressive and antisocial behavior. <i>Psychiatry Research</i> , 1997, 69, 71-77.	3.3	203
12	Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol on Hostility Among Patients With Schizophrenia. <i>Psychiatric Services</i> , 2001, 52, 1510-1514.	2.0	177
13	Association between the functional variant of the catechol-O-methyltransferase (COMT) gene and type 1 alcoholism. <i>Molecular Psychiatry</i> , 1999, 4, 286-289.	7.9	173
14	Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. <i>British Journal of Psychiatry</i> , 2008, 193, 37-43.	2.8	171
15	Overt Aggression and Psychotic Symptoms in Patients With Schizophrenia Treated With Clozapine, Olanzapine, Risperidone, or Haloperidol. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 225-228.	1.4	160
16	Psychopathology and violence: A review of literature. <i>Comprehensive Psychiatry</i> , 1986, 27, 131-148.	3.1	156
17	A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia. <i>Neuropsychopharmacology</i> , 2009, 34, 1322-1329.	5.4	155
18	Pathways to Aggression in Schizophrenia Affect Results of Treatment. <i>Schizophrenia Bulletin</i> , 2011, 37, 921-929.	4.3	154

#	ARTICLE	IF	CITATIONS
19	The Neurobiology of Violence. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1999, 11, 307-314.	1.8	152
20	Prolactin Levels in Schizophrenia and Schizoaffective Disorder Patients Treated With Clozapine, Olanzapine, Risperidone, or Haloperidol. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 57-61.	2.2	151
21	Electroencephalograms in Children of Alcoholic Fathers. <i>Psychophysiology</i> , 1982, 19, 404-407.	2.4	149
22	Antipsychotic-Induced Weight Gain and Therapeutic Response: A Differential Association. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 244-251.	1.4	149
23	Medication Nonadherence and Treatment Outcome in Patients With Schizophrenia or Schizoaffective Disorder With Suboptimal Prior Response. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 990-996.	2.2	139
24	Psychopathy and Violent Behavior Among Patients With Schizophrenia or Schizoaffective Disorder. <i>Psychiatric Services</i> , 1999, 50, 787-792.	2.0	127
25	Catecholamines and Aggression: The Role of COMT and MAO Polymorphisms. <i>Annals of the New York Academy of Sciences</i> , 2004, 1036, 393-398.	3.8	123
26	Characteristics of Assaultive Behavior Among Psychiatric Inpatients. <i>Psychiatric Services</i> , 2003, 54, 1012-1016.	2.0	121
27	Naloxone in chronic schizophrenia. <i>Science</i> , 1977, 196, 1227-1228.	12.6	120
28	Effect of Risperidone on Hostility in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 1995, 15, 243-249.	1.4	119
29	The Electroencephalogram After Alcohol Administration in High-Risk Men and the Development of Alcohol Use Disorders 10 Years Later. <i>Archives of General Psychiatry</i> , 1996, 53, 258.	12.3	118
30	Profile of Mood States: The Factors and Their Physiological Correlates. <i>Journal of Nervous and Mental Disease</i> , 1979, 167, 612-614.	1.0	115
31	Haloperidol Blood Levels and Clinical Effects. <i>Archives of General Psychiatry</i> , 1992, 49, 354.	12.3	114
32	Clomipramine and imipramine in obsessive-compulsive disorder. <i>Psychiatry Research</i> , 1985, 14, 85-93.	3.3	112
33	Lamotrigine as Add-On Therapy in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 582-589.	1.4	112
34	History of violent behaviour and schizophrenia in different cultures. <i>British Journal of Psychiatry</i> , 1997, 171, 9-14.	2.8	105
35	Short-term hormonal effects of naloxone in man. <i>Psychoneuroendocrinology</i> , 1980, 5, 225-234.	2.7	104
36	Suicidal behavior in patients with schizophrenia is related to COMT polymorphism. <i>Psychiatric Genetics</i> , 2000, 10, 117-124.	1.1	96

#	ARTICLE	IF	CITATIONS
37	Violence in schizophrenia and bipolar disorder. <i>Psychiatria Danubina</i> , 2013, 25, 24-33.	0.4	96
38	The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. <i>Neuroscience Letters</i> , 2005, 379, 81-89.	2.1	93
39	Standard and Higher Dose of Olanzapine in Patients With Schizophrenia or Schizoaffective Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 392-400.	1.4	89
40	Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies. <i>European Neuropsychopharmacology</i> , 2015, 25, 1158-1166.	0.7	84
41	Multiple-dose pharmacokinetics of clozapine in patients. <i>Pharmaceutical Research</i> , 1987, 04, 402-405.	3.5	81
42	Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder. <i>Psychiatry Research - Neuroimaging</i> , 2005, 140, 133-145.	1.8	79
43	HIV seroprevalence and risk behaviors in psychiatric inpatients. <i>Psychiatry Research</i> , 1991, 39, 109-114.	3.3	78
44	Optimal Dosing of Atypical Antipsychotics in Adults: A Review of the Current Evidence. <i>Harvard Review of Psychiatry</i> , 2002, 10, 280-291.	2.1	78
45	Clozapine Effects on Hostility and Aggression in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 1993, 13, 287-288.	1.4	76
46	The relationship between history of violent and criminal behavior and recognition of facial expression of emotions in men with schizophrenia and schizoaffective disorder. <i>Aggressive Behavior</i> , 2006, 32, 187-194.	2.4	69
47	Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1917-1928.	1.8	69
48	BMY 14802, a Sigma Receptor Ligand for the Treatment of Schizophrenia. <i>Neuropsychopharmacology</i> , 1994, 10, 37-40.	5.4	66
49	Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder. <i>Journal of Psychiatric Research</i> , 2005, 39, 109-115.	3.1	65
50	The measurement of subjective experience in schizophrenia: The subjective deficit syndrome scale. <i>Comprehensive Psychiatry</i> , 1990, 31, 216-226.	3.1	63
51	Tryptophan treatment of aggressive psychiatric inpatients. <i>Biological Psychiatry</i> , 1990, 28, 728-732.	1.3	60
52	Lack of association between the functional variant of the catechol-o-methyltransferase (COMT) gene and early-onset alcoholism associated with severe antisocial behavior. <i>American Journal of Medical Genetics Part A</i> , 2000, 96, 348-352.	2.4	60
53	Suggestive association between the C825T polymorphism of the G-protein $\beta 3$ subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. <i>European Neuropsychopharmacology</i> , 2005, 15, 525-531.	0.7	59
54	Effects of Atypical Antipsychotics on the Syndromal Profile in Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 551-556.	2.2	59

#	ARTICLE	IF	CITATIONS
55	Violent Behavior in Mental Illness: The Role of Substance Abuse. JAMA - Journal of the American Medical Association, 2010, 304, 563.	7.4	56
56	The psychopharmacology of violence: making sensible decisions. CNS Spectrums, 2014, 19, 411-418.	1.2	56
57	Olanzapine in Refractory Schizophrenia After Failure of Typical or Atypical Antipsychotic Treatment. Journal of Clinical Psychiatry, 2002, 63, 931-935.	2.2	54
58	Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns. Schizophrenia Research, 1999, 35, S23-S33.	2.0	52
59	Placebo or Active Control Trials of Antipsychotic Drugs?. Archives of General Psychiatry, 2003, 60, 458.	12.3	52
60	Pretreatment EEG predicts short-term response to haloperidol treatment. Biological Psychiatry, 1991, 30, 927-942.	1.3	51
61	VIOLENT PATIENTS IN THE EMERGENCY SETTING. Psychiatric Clinics of North America, 1999, 22, 789-801.	1.3	49
62	Plasma Haloperidol Levels and Clinical Effects in Schizophrenia and Schizoaffective Disorder. Archives of General Psychiatry, 1995, 52, 837.	12.3	48
63	Family and case-control association study of the tumor necrosis factor-alpha (TNF- α) gene with schizophrenia and response to antipsychotic medication. Psychopharmacology, 2006, 188, 171-182.	3.1	48
64	Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO). European Psychiatry, 2005, 20, 403-408.	0.2	47
65	Review of Haloperidol Blood Level and Clinical Response. Journal of Clinical Psychopharmacology, 1987, 7, 25-30.	1.4	46
66	Quantitative Electroencephalogram Examination of Effects of Risperidone in Schizophrenic Patients. Journal of Clinical Psychopharmacology, 1993, 13, 332-342.	1.4	43
67	Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. International Clinical Psychopharmacology, 2007, 22, 356-362.	1.7	43
68	Efficacy of Antipsychotic Drugs Against Hostility in the European First-Episode Schizophrenia Trial (EUFEST). Journal of Clinical Psychiatry, 2011, 72, 955-961.	2.2	43
69	A Meta-Analysis of the Val158Met COMT Polymorphism and Violent Behavior in Schizophrenia. PLoS ONE, 2012, 7, e43423.	2.5	42
70	Acute Mania: Haloperidol Dose and Augmentation With Lithium or Lorazepam. Journal of Clinical Psychopharmacology, 1999, 19, 500-505.	1.4	42
71	Pharmacoepidemiology of Clozapine in 202 Inpatients with Schizophrenia. Annals of Pharmacotherapy, 1993, 27, 1262-1269.	1.9	42
72	An association between a polymorphism of the tryptophan hydroxylase gene and aggression in schizophrenia and schizoaffective disorder. Psychiatric Genetics, 2000, 10, 109-115.	1.1	41

#	ARTICLE	IF	CITATIONS
73	Course of Patients With Histories of Aggression and Crime After Discharge From a Cognitive-Behavioral Program. <i>Psychiatric Services</i> , 2004, 55, 654-659.	2.0	41
74	Relationship between the brief psychiatric rating scale and the scale for the assessment of negative symptoms: A study of their correlation and redundancy. <i>Psychiatry Research</i> , 1991, 36, 129-139.	3.3	40
75	Pharmacological Management of Acute and Persistent Aggression in Forensic Psychiatry Settings. <i>CNS Drugs</i> , 2011, 25, 1009-1021.	5.9	40
76	EEG and clinical change after bilateral and unilateral electroconvulsive therapy. <i>Electroencephalography and Clinical Neurophysiology</i> , 1972, 32, 631-639.	0.3	39
77	Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes. <i>Psychiatry Research</i> , 1997, 71, 19-26.	3.3	39
78	HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis. <i>Human Psychopharmacology</i> , 2007, 22, 463-467.	1.5	39
79	Aggression and Quantitative MRI Measures of Caudate in Patients With Chronic Schizophrenia or Schizoaffective Disorder. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2006, 18, 509-515.	1.8	38
80	Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone. <i>Neuropsychiatric Disease and Treatment</i> , 2009, 5, 47.	2.2	37
81	Efficacy of Ziprasidone Against Hostility in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 638-642.	2.2	35
82	Comorbid Personality Disorders and Violent Behavior in Psychotic Patients. <i>Psychiatric Quarterly</i> , 2014, 85, 65-78.	2.1	34
83	Efficacy of Aripiprazole Against Hostility in Schizophrenia and Schizoaffective Disorder. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1362-1366.	2.2	34
84	Predicting Assaultiveness in Psychiatric Inpatients: A Pilot Study. <i>Psychiatric Services</i> , 1988, 39, 429-434.	2.0	33
85	Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. <i>CNS Spectrums</i> , 2014, 19, 374-381.	1.2	33
86	Inpatient violence: Trait and state. <i>Journal of Psychiatric Research</i> , 1989, 23, 57-64.	3.1	32
87	MARIJUANA, EEG, AND BEHAVIOR. <i>Annals of the New York Academy of Sciences</i> , 1971, 191, 206-215.	3.8	31
88	Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve. <i>Psychiatry Research</i> , 1992, 42, 129-144.	3.3	31
89	Olanzapine for Schizophrenia Refractory to Typical and Atypical Antipsychotics: An Open-Label, Prospective Trial. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 448-453.	1.4	31
90	Managing Treatment-Resistant Schizophrenia: Evidence from Randomized Clinical Trials. <i>Journal of Psychiatric Practice</i> , 2002, 8, 205-215.	0.7	30

#	ARTICLE	IF	CITATIONS
91	EEG seizure patterns during multiple unilateral and bilateral ECT. <i>Comprehensive Psychiatry</i> , 1973, 14, 25-28.	3.1	29
92	Electroencephalographic and other effects of naloxone in normal men.. <i>Life Sciences</i> , 1979, 25, 1267-1272.	4.3	28
93	COMT158 polymorphism and hostility. <i>American Journal of Medical Genetics Part A</i> , 2004, 127B, 28-29.	2.4	28
94	Schizophrenia and violence. <i>Psychological Medicine</i> , 1989, 19, 559-562.	4.5	27
95	Effects of caffeine on resting EEG and response to sine wave modulated light. <i>Electroencephalography and Clinical Neurophysiology</i> , 1981, 51, 470-476.	0.3	26
96	Underreporting of Physical Assaults in Schizophrenic Inpatients. <i>Journal of Nervous and Mental Disease</i> , 1988, 176, 507-509.	1.0	26
97	Dimensions of the brief psychiatric rating scale: An examination of stability during haloperidol treatment. <i>Comprehensive Psychiatry</i> , 1996, 37, 205-215.	3.1	25
98	High-Dose Treatment With Haloperidol: The Effect of Dose Reduction. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 252-256.	1.4	25
99	Psychobiology of the Violent Offender. <i>Journal of Forensic Sciences</i> , 1992, 37, 237-251.	1.6	25
100	Late-onset schizophrenia: A review. <i>Comprehensive Psychiatry</i> , 1985, 26, 148-156.	3.1	24
101	IQ scores of treatment-resistant schizophrenia patients before and after the onset of the illness. <i>Schizophrenia Research</i> , 2000, 46, 203-207.	2.0	24
102	Psychiatric patients with histories of aggression and crime five years after discharge from a cognitive-behavioral program. <i>Journal of Forensic Psychiatry and Psychology</i> , 2010, 21, 167-188.	1.0	24
103	Very long-term outcome of schizophrenia. <i>International Journal of Clinical Practice</i> , 2018, 72, e13094.	1.7	24
104	The EEG in Persons at Risk for Alcoholism. , 1985, 3, 21-36.		24
105	Dissociation, Cognitive Reflection and Health Literacy Have a Modest Effect on Belief in Conspiracy Theories about COVID-19. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 5065.	2.6	23
106	Atypical antipsychotics: revolutionary or incremental advance?. <i>Expert Review of Neurotherapeutics</i> , 2002, 2, 69-88.	2.8	22
107	The promise of atypical antipsychotics. <i>Postgraduate Medicine</i> , 2004, 116, 49-63.	2.0	20
108	Electroencephalograms of XYY and XXY Men. <i>British Journal of Psychiatry</i> , 1977, 130, 43-47.	2.8	19

#	ARTICLE	IF	CITATIONS
109	METHADONE DOSE, PLASMA LEVEL, AND CROSS-TOLERANCE TO HEROIN IN MAN. <i>Journal of Nervous and Mental Disease</i> , 1978, 166, 104-109.	1.0	19
110	Effect of piracetam on EEG spectra of boys with learning disorders. <i>Psychopharmacology</i> , 1981, 72, 185-188.	3.1	19
111	Staff and Patient Views of the Reasons for Aggressive Incidents: A Prospective, Incident-Based Study. <i>Psychiatric Quarterly</i> , 2009, 80, 167-172.	2.1	19
112	Measurement of agitation and aggression in adult and aged neuropsychiatric patients: review of definitions and frequently used measurement scales. <i>CNS Spectrums</i> , 2017, 22, 407-414.	1.2	19
113	Psychopharmacology of Violence: Part II: Beyond the Acute Episode. <i>Psychiatric Annals</i> , 1997, 27, 696-703.	0.1	18
114	Management of Violence in Schizophrenia. <i>Psychiatric Annals</i> , 2000, 30, 41-52.	0.1	18
115	NALOXONE AND NALTREXONE IN MENTAL ILLNESS AND TARDIVE DYSKINESIA. <i>Annals of the New York Academy of Sciences</i> , 1982, 398, 97-102.	3.8	17
116	Short-lived effect of (des-tyr)-gamma-endorphin in schizophrenia. <i>Psychiatry Research</i> , 1983, 10, 243-252.	3.3	17
117	Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies. <i>European Psychiatry</i> , 2016, 31, 13-19.	0.2	17
118	Short-Term Effects of Heroin in Man. <i>Archives of General Psychiatry</i> , 1974, 30, 677.	12.3	16
119	Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder. <i>Psychiatry Research</i> , 1998, 81, 51-55.	3.3	16
120	Naloxone, tardive dyskinesia, and endogenous beta-endorphin. <i>Psychiatry Research</i> , 1982, 7, 321-324.	3.3	15
121	Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes: Response to consensus statement. <i>Diabetes Care</i> , 2004, 27, 2087-2088.	8.6	15
122	EEG spectra in XYY and XXY men. <i>Electroencephalography and Clinical Neurophysiology</i> , 1977, 43, 798-801.	0.3	14
123	Validity of Self-Reports of Criminal Activity in Psychiatric Inpatients. <i>Journal of Nervous and Mental Disease</i> , 1990, 178, 48-51.	1.0	14
124	Insight and Hostility as Predictors and Correlates of Nonadherence in the European First Episode Schizophrenia Trial. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 258-261.	1.4	14
125	Schizophrenia: violence and comorbidity. <i>Current Opinion in Psychiatry</i> , 1999, 12, 47-51.	6.3	14
126	Psychopharmacology of Violence: Part I: Assessment and Acute Treatment. <i>Psychiatric Annals</i> , 1997, 27, 691-695.	0.1	14

#	ARTICLE	IF	CITATIONS
127	Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Journal of Clinical Psychiatry, 2005, 66, 1073-1074.	2.2	14
128	Concurrent lithium administration results in higher haloperidol levels in brain and plasma of guinea pigs. Psychiatry Research, 1987, 20, 313-316.	3.3	13
129	Serotonin in violent patients with schizophrenia. Psychiatry Research, 1995, 59, 161-163.	3.3	13
130	Hypothesis testing: Is clozapine's superior efficacy dependent on moderate D2 receptor occupancy?. Biological Psychiatry, 1998, 43, 79-83.	1.3	13
131	Are all antipsychotics equal?. Lancet, The, 2008, 372, 201-202.	13.7	13
132	ACTH 4â€“10: a Study of Toxicological and Behavioral Effects in an Aging Sample. Neuropsychobiology, 1976, 2, 350-360.	1.9	12
133	Differential regulation of catechol-O-methyltransferase expression in a mouse model of aggression. Brain Structure and Function, 2011, 216, 347-356.	2.3	11
134	Triggering Violence in Psychosis. JAMA Psychiatry, 2016, 73, 769.	11.0	11
135	Specific Anti-hostility Effects of Atypical Antipsychotics in Persons with Schizophrenia: From Clozapine to Cariprazine. Harvard Review of Psychiatry, 2021, 29, 20-34.	2.1	11
136	Antiaggressive Effect of Quetiapine in a Patient With Schizoaffective Disorder. Journal of Clinical Psychiatry, 2001, 62, 901.	2.2	11
137	Electroencephalogram among criminals. , 1987, , 137-145.		10
138	Genetic interactions in the adrenergic system genes: analysis of antipsychoticâ€“induced weight gain. Human Psychopharmacology, 2011, 26, 386-391.	1.5	10
139	Aggression in Psychoses. Advances in Psychiatry, 2014, 2014, 1-20.	0.4	10
140	Opiates and Antagonists. , 1971, , 452-467.		10
141	Action of Naloxone and Naltrexone in Different Types of Psychoses. Modern Problems of Pharmacopsychiatry, 1981, 17, 202-212.	2.5	9
142	Lithium and lecithin in tardive dyskinesia: An update. Psychiatry Research, 1986, 19, 101-104.	3.3	9
143	Overt Aggression and Psychotic Symptoms in Patients With Schizophrenia Treated With Clozapine, Olanzapine, Risperidone, or Haloperidol. Journal of Clinical Psychopharmacology, 2004, 24, 1-4.	1.4	9
144	Video Recording in the Assessment of Violent Incidents in Psychiatric Hospitals. Journal of Psychiatric Practice, 2006, 12, 58-63.	0.7	9

#	ARTICLE	IF	CITATIONS
145	Effect of nitrazepam, amylobarbitone sodium and placebo on the electroencephalogram of normal subjects. <i>Psychopharmacology</i> , 1969, 14, 178-183.	3.1	8
146	Identification of a naturally occurring 21bp deletion in alpha2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment. <i>Pharmacological Research</i> , 2005, 51, 381-384.	7.1	8
147	Violent Crime, Epilepsy, and Traumatic Brain Injury. <i>PLoS Medicine</i> , 2011, 8, e1001148.	8.4	8
148	Prediction of Violence in Psychiatric Inpatients. , 1988, , 223-245.		8
149	Willingness to Vaccinate Against COVID-19: The Role of Health Locus of Control and Conspiracy Theories. <i>Frontiers in Psychology</i> , 2021, 12, 717960.	2.1	8
150	Pattern reversal visual evoked potentials after alcohol administration among men at risk for alcoholism. <i>Psychiatry Research</i> , 1988, 26, 191-202.	3.3	7
151	Methodological Structure for Aggression Research. <i>Psychiatric Quarterly</i> , 2008, 79, 293-300.	2.1	7
152	Clozapine is gold standard, but questions remain. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 1201-1204.	2.1	7
153	A Prospective Study of Alcoholism: Electroencephalographic Findings. , 1984, , 125-145.		7
154	Brief Pulse ECT in Melancholia. <i>Journal of Nervous and Mental Disease</i> , 1992, 180, 55-57.	1.0	6
155	Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation. <i>Schizophrenia Research</i> , 2005, 76, 127-129.	2.0	6
156	Teaching Critical Appraisal of Articles on Psychopharmacology. <i>Academic Psychiatry</i> , 2012, 36, 114-7.	0.9	6
157	Catechol-O-methyltransferase and Monoamine Oxidase-A Polymorphisms and Treatment Response to Typical and Atypical Neuroleptics. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 338-340.	1.4	5
158	Review: 15 antipsychotic drugs are more effective than placebo for the treatment of schizophrenia, but vary in their tolerability. <i>Evidence-Based Mental Health</i> , 2014, 17, 9-9.	4.5	5
159	Deconstructing violence in acutely exacerbating psychotic patients. <i>CNS Spectrums</i> , 2020, , 1-5.	1.2	5
160	Violence in Schizophrenia. <i>Journal of Psychiatric Practice</i> , 1999, 5, 326-335.	0.7	4
161	Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study – ADDENDUM. <i>CNS Spectrums</i> , 2014, 19, 466-466.	1.2	4
162	Preventing Violence in Patients with Schizophrenia. <i>Current Treatment Options in Psychiatry</i> , 2015, 2, 182-191.	1.9	4

#	ARTICLE	IF	CITATIONS
163	Violence in the Mentally Ill: Questions Remain. Archives of General Psychiatry, 1999, 56, 193.	12.3	4
164	Risk for Individuals With Schizophrenia Who Are Living in the Community. Psychiatric Services, 2002, 53, 484-485.	2.0	4
165	Does the change of psychopathology during the placebo period predict the response to subsequent treatment with active medication?. Psychiatry Research, 1994, 52, 107-114.	3.3	3
166	Haloperidol Blood Levels in Acute Mania With Psychosis. Journal of Clinical Psychopharmacology, 2001, 21, 445-447.	1.4	3
167	Serious physical assault and subsequent risk for rehospitalization in individuals with severe mental illness: a nationwide, register-based retrospective cohort study. Annals of General Psychiatry, 2021, 20, 44.	2.7	3
168	Genetic and Neurochemical Correlates of Violence. Psychiatric Annals, 1997, 27, 679-682.	0.1	3
169	Minor physical anomalies in violent adult inpatients. Biological Psychiatry, 1987, 22, 1166-1168.	1.3	2
170	Pharmacological Interventions for Preventing Violence Among the Mentally Ill with Co-Occurring Personality Disorders. , 2000, , 193-209.		2
171	Olanzapine vs Haloperidol for Treatment of Schizophrenia. JAMA - Journal of the American Medical Association, 2004, 291, 1064.	7.4	1
172	All Antipsychotics Are Equal, but Some Are More Equal Than Others. Journal of Clinical Psychiatry, 2009, 70, 429-430.	2.2	1
173	Screaming and Physical Aggression in Nursing Homes. American Journal of Geriatric Psychiatry, 2005, 13, 539-540.	1.2	1
174	Marijuana, hashish and tetrahydrocannabinol- δ^9 : effects on EEG, heart rate and mood. Journal of Psychiatric Research, 1974, 10, 159.	3.1	0
175	Effects of L-alpha-acetylmethadol (LAAM) and Methadone on Human EEG. Clinical EEG (electroencephalography), 1976, 7, 198-202.	0.9	0
176	Understanding EEG: An Introduction to Electroencephalography. American Journal of Psychiatry, 1977, 134, 1062-1062.	7.2	0
177	Drs. Volavka and Mallya Reply. American Journal of Psychiatry, 1979, 136, 1229-1229.	7.2	0
178	Lithium and cholinomimetics. Biological Psychiatry, 1989, 26, 650-651.	1.3	0
179	Dr. Krakowski and Associates Reply. American Journal of Psychiatry, 1990, 147, 1384-1385.	7.2	0
180	Are Extrapyramidal Symptoms Necessary for Antipsychotic Activity???? Reply. Journal of Clinical Psychopharmacology, 1992, 12, 65.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Inhibition of pyruvate dehydrogenase complex by antipsychotic drugs. <i>Biological Psychiatry</i> , 1992, 31, 99-100.	1.3	0
182	Placebo Reconsidered. <i>Canadian Journal of Psychiatry</i> , 1995, 40, 426-427.	1.9	0
183	Ambulatory Electroconvulsive Therapy. Review of Russian Translation of a 1996 Report of an Association for Convulsive Therapy Task Force. <i>Journal of ECT</i> , 2007, 23, 128-129.	0.6	0
184	Why is ITAREPS successful?. <i>Schizophrenia Research</i> , 2014, 152, 530.	2.0	0
185	Understanding the Risk of Treatment Failure After Discontinuation of Long-Term Antipsychotic Treatment. <i>American Journal of Psychiatry</i> , 2018, 175, 908-909.	7.2	0
186	Psychopharmacology of Violence. , 0, , 645-653.		0
187	Dr. Bilder and Colleagues Reply. <i>American Journal of Psychiatry</i> , 2002, 159, 2118-a-2119.	7.2	0
188	Eficacia de la monoterapia de clozapina, olanzapina, quetiapina, risperidona y haloperidol en la reducci3n del comportamiento hostil y agresivo en pacientes ambulatorios tratados por esquizofrenia: un estudio naturalista prospectivo (IC-SOHO). <i>European Psychiatry (Ed Espa±ola)</i> , 2006, 13, 70-76.	0.0	0
189	Psychopharmacology of Violent Behavior Among People with Severe Mental Disorders. <i>Comprehensive Approach To Psychiatry</i> , 2020, , 253-268.	1.0	0